The KEYNOTE-905 study is ongoing and will evaluate other endpoints including EFS, OS, and pCR rate for neoadjuvant and adjuvant pembrolizumab vs surgery alone.

Discordance was greater for middle-aged adults, racial and ethnic minorities, and for those with lower educational attainment.